par Agathe Masson | Oct 23, 2025 | Access to Care, NCD Solutions, Actualités
Rituximab, a life-saving monoclonal antibody used in the treatment of blood cancers, is now available as a biosimilar through NCDconnect, ensuring quality, affordability, and access to targeted cancer therapies across low- and middle-income countries (LMICs). Pharmacy...
par Agathe Masson | Juil 15, 2025 | Access to Care, NCD Solutions, Actualités
The collaboration between IDA Foundation’s NCDconnect initiative and the Access to Oncology Medicines (ATOM) Coalition, led by the Union for International Cancer Control (UICC), is making significant strides toward improving access to cancer care in low- and...
par Agathe Masson | Déc 16, 2024 | NCD Solutions, Actualités
Welcome to NCDconnect, your Digital Procurement Platform for essential medicines and medical devices against noncommunicable diseases (NCD). Signing up is straightforward, and this guide will help you complete the process with ease. Who can Use NCDconnect’s...
par Agathe Masson | Déc 13, 2024 | Access to Care, NCD Solutions, Actualités
Every child deserves a fighting chance against cancer, regardless of where they are born. Yet, stark inequalities persist in access to pediatric oncology treatment, especially in low- and middle-income countries (LMICs). As purchasers responsible for securing...
par Agathe Masson | Déc 9, 2024 | Access to Care, NCD Solutions, Actualités
Sickle Cell Disease (SCD) is a genetic blood disorder that affects millions of people worldwide. Between 2010 and 2050, an estimated 14 million babies will be affected globally, with the vast majority born in low- and middle-income countries (LMICs). This staggering...
par Callie Weber | Fév 9, 2024 | NCD Partnerships, NCD Solutions, Actualités
Have you heard about NCDconnect? Through the innovative NCDconnect platform, IDA Foundation and Solvoz have formed a strategic partnership, united in their mission to streamline the procurement of high-quality NCD medicines, medical supplies, and diagnostics. Serving...
